IL6 and breast carcinoma: Our findings suggest there is a robust, IL-6-dependent polarization toward type 3 immunity, which accompanies MDSC expansion in this mammary carcinoma model, and that this altered Th cell landscape should be considered to improve immune and other oncotherapies.